Takeo Yoshikawa

Find an error

Name:
Organization: Riken , Japan
Department: Laboratory of Molecular Psychiatry
Title: (PhD)
Co-reporter:Shabeesh Balan, Kazuo Yamada, Yoshimi Iwayama, Takanori Hashimoto, Tomoko Toyota, Chie Shimamoto, Motoko Maekawa, Shu Takagai, Tomoyasu Wakuda, Yosuke Kameno, Daisuke Kurita, Kohei Yamada, Mitsuru Kikuchi, Tasuku Hashimoto, Nobuhisa Kanahara, Takeo Yoshikawa
Schizophrenia Research 2017 Volume 185(Volume 185) pp:
Publication Date(Web):1 July 2017
DOI:10.1016/j.schres.2017.01.003
Involvement of the gamma-aminobutyric acid (GABA)-ergic system in schizophrenia pathogenesis through disrupted neurodevelopment has been highlighted in numerous studies. However, the function of common genetic variants of this system in determining schizophrenia risk is unknown. We therefore tested the association of 375 tagged SNPs in genes derived from the GABAergic system, such as GABAA receptor subunit genes, and GABA related genes (glutamate decarboxylase genes, GABAergic-marker gene, genes involved in GABA receptor trafficking and scaffolding) in Japanese schizophrenia case-control samples (n = 2926; 1415 cases and 1511 controls). We observed nominal association of SNPs in nine GABAA receptor subunit genes and the GPHN gene with schizophrenia, although none survived correction for study-wide multiple testing. Two SNPs located in the GABRA1 gene, rs4263535 (Pallele = 0.002; uncorrected) and rs1157122 (Pallele = 0.006; uncorrected) showed top hits, followed by rs723432 (Pallele = 0.007; uncorrected) in the GPHN gene. All three were significantly associated with schizophrenia and survived gene-wide multiple testing. Haplotypes containing associated variants in GABRA1 but not GPHN were significantly associated with schizophrenia. To conclude, we provided substantiating genetic evidence for the involvement of the GABAergic system in schizophrenia susceptibility. These results warrant further investigations to replicate the association of GABRA1 and GPHN with schizophrenia and to discern the precise mechanisms of disease pathophysiology.
Co-reporter:M Toyoshima, W Akamatsu, Y Okada, T Ohnishi, S Balan, Y Hisano, Y Iwayama, T Toyota, T Matsumoto, N Itasaka, S Sugiyama, M Tanaka, M Yano, B Dean, H Okano and T Yoshikawa
Translational Psychiatry 2016 Volume 6(Nov) pp:e934
Publication Date(Web):2016-11-01
DOI:10.1038/tp.2016.206
Given the complexity and heterogeneity of the genomic architecture underlying schizophrenia, molecular analyses of these patients with defined and large effect-size genomic defects could provide valuable clues. We established human-induced pluripotent stem cells from two schizophrenia patients with the 22q11.2 deletion (two cell lines from each subject, total of four cell lines) and three controls (total of four cell lines). Neurosphere size, neural differentiation efficiency, neurite outgrowth, cellular migration and the neurogenic-to-gliogenic competence ratio were significantly reduced in patient-derived cells. As an underlying mechanism, we focused on the role of DGCR8, a key gene for microRNA (miRNA) processing and mapped in the deleted region. In mice, Dgcr8 hetero-knockout is known to show a similar phenotype of reduced neurosphere size (Ouchi et al., 2013). The miRNA profiling detected reduced expression levels of miRNAs belonging to miR-17/92 cluster and miR-106a/b in the patient-derived neurospheres. Those miRNAs are reported to target p38α, and conformingly the levels of p38α were upregulated in the patient-derived cells. p38α is known to drive gliogenic differentiation. The inhibition of p38 activity by SB203580 in patient-derived neurospheres partially restored neurogenic competence. Furthermore, we detected elevated expression of GFAP, a gliogenic (astrocyte) marker, in postmortem brains from schizophrenia patients without the 22q11.2 deletion, whereas inflammation markers (IL1B and IL6) remained unchanged. In contrast, a neuronal marker, MAP2 expressions were decreased in schizophrenia brains. These results suggest that a dysregulated balance of neurogenic-to-gliogenic competence may underlie neurodevelopmental disorders such as schizophrenia.
Co-reporter:Shabeesh Balan;Yoshimi Iwayama;Kazuo Yamada
Journal of Neural Transmission 2015 Volume 122( Issue 3) pp:477-485
Publication Date(Web):2015 March
DOI:10.1007/s00702-014-1269-0
Disruption of synaptic networks has been advocated in the pathogenesis of psychiatric diseases like schizophrenia. The majority of synaptic proteins involved in neuronal communications are localized in lipid rafts. These rafts form the platform for coordinating neuronal signal transduction, by clustering interacting partners. The PAG1 protein is a transmembrane adaptor protein in the lipid raft signaling cluster that regulates Src family kinases (SFKs), a convergent point for multiple pathways regulating N-methyl-d-aspartate (NMDA) receptors. Reports of de novo missense mutations in PAG1 and SFK mediated reductions in tyrosine phosphorylation of NMDA receptor subunit proteins in schizophrenia patients, point to a putative role in schizophrenia pathogenesis. To evaluate this, we resequenced the entire coding region of PAG1 in Japanese schizophrenia patients (n = 1,140) and controls (n = 1,140). We identified eight missense variants, of which four were previously unreported. Case–control genetic association analysis of these variants in a larger cohort (n = 4,182) showed neither a statistically significant association of the individual variants with schizophrenia, nor any increased burden of the rare alleles in the patient group. Expression levels of PAG1 in post-mortem brain samples from schizophrenia patients and controls also showed no significant differences. To assess the precise role of PAG1 in schizophrenia, future studies with larger sample sizes are needed.
Co-reporter:Shabeesh Balan;Motoko Maekawa;Yoshimi Iwayama;Takeo Yoshikawa;Norio Mori;Masayuki Ide;Motonori Ota;Satoshi Fukuchi;Masatsugu Tsujii;Yoichi Shinkai;Katsuaki Suzuki;Yasuhide Iwata;Kazuo Yamada;Kayoko Esaki;Chie Shimamoto;Manabu Toyoshima;Tomoko Toyota;Tetsuo Ohnishi
Molecular Autism 2014 Volume 5( Issue 1) pp:
Publication Date(Web):2014/12/01
DOI:10.1186/2040-2392-5-49
Histone H3 methylation at lysine 9 (H3K9) is a conserved epigenetic signal, mediating heterochromatin formation by trimethylation, and transcriptional silencing by dimethylation. Defective GLP (Ehmt1) and G9a (Ehmt2) histone lysine methyltransferases, involved in mono and dimethylation of H3K9, confer autistic phenotypes and behavioral abnormalities in animal models. Moreover, EHMT1 loss of function results in Kleefstra syndrome, characterized by severe intellectual disability, developmental delays and psychiatric disorders. We examined the possible role of histone methyltransferases in the etiology of autism spectrum disorders (ASD) and suggest that rare functional variants in these genes that regulate H3K9 methylation may be associated with ASD.Since G9a-GLP-Wiz forms a heteromeric methyltransferase complex, all the protein-coding regions and exon/intron boundaries of EHMT1, EHMT2 and WIZ were sequenced in Japanese ASD subjects. The detected variants were prioritized based on novelty and functionality. The expression levels of these genes were tested in blood cells and postmortem brain samples from ASD and control subjects. Expression of EHMT1 and EHMT2 isoforms were determined by digital PCR.We identified six nonsynonymous variants: three in EHMT1, two in EHMT2 and one in WIZ. Two variants, the EHMT1 ankyrin repeat domain (Lys968Arg) and EHMT2 SET domain (Thr961Ile) variants were present exclusively in cases, but showed no statistically significant association with ASD. The EHMT2 transcript expression was significantly elevated in the peripheral blood cells of ASD when compared with control samples; but not for EHMT1 and WIZ. Gene expression levels of EHMT1, EHMT2 and WIZ in Brodmann area (BA) 9, BA21, BA40 and the dorsal raphe nucleus (DoRN) regions from postmortem brain samples showed no significant changes between ASD and control subjects. Nor did expression levels of EHMT1 and EHMT2 isoforms in the prefrontal cortex differ significantly between ASD and control groups.We identified two novel rare missense variants in the EHMT1 and EHMT2 genes of ASD patients. We surmise that these variants alone may not be sufficient to exert a significant effect on ASD pathogenesis. The elevated expression of EHMT2 in the peripheral blood cells may support the notion of a restrictive chromatin state in ASD, similar to schizophrenia.
Co-reporter:Daisuke Jitoku;Eiji Hattori;Yoshimi Iwayama;Kazuo Yamada;Tomoko Toyota;Mitsuru Kikuchi;Motoko Maekawa;Toru Nishikawa
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2011 Volume 156( Issue 5) pp:581-592
Publication Date(Web):
DOI:10.1002/ajmg.b.31199

Abstract

Many studies have suggested that myelin dysfunction may be causally involved in the pathogenesis of schizophrenia. Nogo (RTN4), myelin-associated glycoprotein (MAG) and oligodendrocyte myelin glycoprotein (OMG) all bind to the common receptor, Nogo-66 receptor 1 (RTN4R). We examined 68 single nucleotide polymorphisms (SNPs) (51 with genotyping and 17 with imputation analysis) from these four genes for genetic association with schizophrenia, using a 2,120 case–control sample from the Japanese population. Allelic tests showed nominally significant association of two RTN4 SNPs (P = 0.047 and 0.037 for rs11894868 and rs2968804, respectively) and two MAG SNPs (P = 0.034 and 0.029 for rs7249617 and rs16970218, respectively) with schizophrenia. The MAG SNP rs7249617 also showed nominal significance in a genotypic test (P = 0.017). In haplotype analysis, the MAG haplotype block including rs7249617 and rs16970218 showed nominal significance (P = 0.008). These associations did not remain significant after correction for multiple testing, possibly due to their small genetic effect. In the imputation analysis of RTN4, the untyped SNP rs2972090 showed nominally significant association (P = 0.032) and several imputed SNPs showed marginal associations. Moreover, in silico analysis (PolyPhen) of a missense variant (rs11677099: Asp357Val), which is in strong linkage disequilibrium with rs11894868, predicted a deleterious effect on Nogo protein function. Despite a failure to detect robust associations in this Japanese cohort, our nominally positive signals, taken together with previously reported biological and genetic findings, add further support to the “disturbed myelin system theory of schizophrenia” across different populations. © 2011 Wiley-Liss, Inc.

Co-reporter:Yoshimi Iwayama;Eiji Hattori;Motoko Maekawa;Kazuo Yamada;Tomoko Toyota;Tetsuo Ohnishi;Yasuhide Iwata;Kenji J. Tsuchiya;Genichi Sugihara;Mitsuru Kikuchi;Kenji Hashimoto;Masaomi Iyo;Toshiya Inada;Hiroshi Kunugi;Norio Ozaki;Nakao Iwata;Shinichiro Nanko;Kazuya Iwamoto;Yuji Okazaki;Tadafumi Kato
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2010 Volume 153B( Issue 2) pp:484-493
Publication Date(Web):
DOI:10.1002/ajmg.b.31004

Abstract

Deficits in prepulse inhibition (PPI) are a biological marker for psychiatric illnesses such as schizophrenia and bipolar disorder. To unravel PPI-controlling mechanisms, we previously performed quantitative trait loci (QTL) analysis in mice, and identified Fabp7, that encodes a brain-type fatty acid binding protein (Fabp), as a causative gene. In that study, human FABP7 showed genetic association with schizophrenia. FABPs constitute a gene family, of which members FABP5 and FABP3 are also expressed in the brain. These FABP proteins are molecular chaperons for polyunsaturated fatty acids (PUFAs) such as arachidonic and docosahexaenoic acids. Additionally, the involvement of PUFAs has been documented in the pathophysiology of schizophrenia and mood disorders. Therefore in this study, we examined the genetic roles of FABP5 and 3 in schizophrenia (N = 1,900 in combination with controls) and FABP7, 5, and 3 in bipolar disorder (N = 1,762 in the case–control set). Three single nucleotide polymorphisms (SNPs) from FABP7 showed nominal association with bipolar disorder, and haplotypes of the same gene showed empirical associations with bipolar disorder even after correction of multiple testing. We could not perform association studies on FABP5, due to the lack of informative SNPs. FABP3 displayed no association with either disease. Each FABP is relatively small and it is assumed that there are multiple regulatory elements that control gene expression. Therefore, future identification of unknown regulatory elements will be necessary to make a more detailed analysis of their genetic contribution to mental illnesses. © 2009 Wiley-Liss, Inc.

Co-reporter:Eiji Hattori, Mizuho Nakajima, Kazuo Yamada, Yoshimi Iwayama, Tomoko Toyota, Naruya Saitou and Takeo Yoshikawa
European Journal of Human Genetics 2009 17(6) pp:793-801
Publication Date(Web):December 17, 2008
DOI:10.1038/ejhg.2008.247
Associations have been reported between the variable number of tandem repeat (VNTR) polymorphisms in the exon 3 of dopamine D4 receptor gene gene and multiple psychiatric illnesses/traits. We examined the distribution of VNTR alleles of different length in a Japanese cohort and found that, as reported earlier, the size of allele ‘7R’ was much rarer (0.5%) in Japanese than in Caucasian populations (~20%). This presents a challenge to an earlier proposed hypothesis that positive selection favoring the allele 7R has contributed to its high frequency. To further address the issue of selection, we carried out sequencing of the VNTR region not only from human but also from chimpanzee samples, and made inference on the ancestral repeat motif and haplotype by use of a phylogenetic analysis program. The most common 4R variant was considered to be the ancestral haplotype as earlier proposed. However, in a gene tree of VNTR constructed on the basis of this inferred ancestral haplotype, the allele 7R had five descendent haplotypes in relatively long lineage, where genetic drift can have major influence. We also tested this length polymorphism for association with schizophrenia, studying two Japanese sample sets (one with 570 cases and 570 controls, and the other with 124 pedigrees). No evidence of association between the allele 7R and schizophrenia was found in any of the two data sets. Collectively, this study suggests that the VNTR variation does not have an effect large enough to cause either selection or a detectable association with schizophrenia in a study of samples of moderate size.
Co-reporter:Joanne M A Meerabux, Hisako Ohba, Yoshimi Iwayama, Motoko Maekawa, Sevilla D Detera-Wadleigh, Lynn E DeLisi and Takeo Yoshikawa
Journal of Human Genetics 2009 54(7) pp:386-391
Publication Date(Web):May 22, 2009
DOI:10.1038/jhg.2009.47
It is suggested that chromosome 18p11 is a susceptibility region for both bipolar disorder and schizophrenia. Aiming to identify susceptibility gene(s), we investigated a family whose members have either schizophrenia or schizophrenia-spectrum psychosis and carried a t(18;21)(p11.1;p11.1) translocation. Fluorescence in situ hybridization showed that the breakpoint on chromosome 21 was localized to a bacterial artificial chromosome (BAC) clone RP11-2503J9, which contained coding sequences for transmembrane phosphatase with tensin homology, although this gene was not disrupted. On chromosome 18p, the break point was narrowed to BAC clone RP11-527H14. In silico sequence analysis of this clone identified possible pseudo genes and gene fragments but no intact genes. RP11-527H14 also showed sites of cross hybridization, including 21p11.1. To test for a position effect on 18p11 sequences translocated to 21p11, we performed quantitative RT-PCR to measure the expression of the candidate gene C18orf1 in translocation carriers, but found no significant differences from controls in lymphoblastoid cells.
Co-reporter:Kazuo Yamada;Eiji Hattori;Yoshimi Iwayama;Tomoko Toyota;Tetsuo Ohnishi;Yasuhide Iwata;Kenji J. Tsuchiya;Genichi Sugihara;Mitsuru Kikuchi;Yuji Okazaki
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2009 Volume 150B( Issue 4) pp:508-514
Publication Date(Web):
DOI:10.1002/ajmg.b.30847

Abstract

Recently, three common polymorphisms in the promoter region of the Chitinase 3-Like 1 (CHI3L1) gene, rs6691378, rs10399805 and rs4950928, have been identified as schizophrenia predisposing single nucleotide polymorphisms (SNPs) in the Han Chinese population. The at-risk haplotype comprising these SNPs was also related to decreased expression of CHI3L1 in peripheral blood cells. In contrast, two independent postmortem brain studies have reported elevated expression of the transcript in the hippocampus and prefrontal cortex, from schizophrenic patients. The gene encodes a secreted glycoprotein (HC-gp39 or YKL40), which is deemed to be involved in the inflammatory process. These pieces of evidence signify the potential importance of CHI3L1 in the pathogenesis of schizophrenia. In this study, we aimed to replicate the prior genetic association findings using two sample sets, one set of Chinese samples (293 pedigrees consisting of 1,163 subjects) that are ethnically identical to those used in the original report and a second set from the relatively close Japanese population (570 schizophrenic patients and 570 matched controls). We analyzed the same five SNPs as in the original study, including the three promoter SNPs. None of these SNPs showed association signals with schizophrenia (P values >0.108) in our sample sets. These results suggest that the genetic contribution of CHI3L1 to schizophrenia is variable, even though it is mechanistically involved in the disease process. © 2008 Wiley-Liss, Inc.

Co-reporter:Eiji Hattori;Tomoko Toyota;Yuichi Ishitsuka;Yoshimi Iwayama;Kazuo Yamada;Hiroshi Ujike;Yukitaka Morita;Masafumi Kodama;Kenji Nakata;Yoshio Minabe;Kazuhiko Nakamura;Yasuhide Iwata;Nori Takei;Norio Mori;Hiroshi Naitoh;Yoshio Yamanouchi;Nakao Iwata;Norio Ozaki;Tadafumi Kato;Toru Nishikawa;Atsushi Kashiwa;Mika Suzuki;Kunihiko Shioe;Manabu Shinohara;Masami Hirano;Shinichiro Nanko;Akihisa Akahane;Mikako Ueno;Naoshi Kaneko;Yuichiro Watanabe;Toshiyuki Someya;Kenji Hashimoto;Masaomi Iyo;Masanari Itokawa;Makoto Arai;Masahiro Nankai;Toshiya Inada;Sumiko Yoshida;Hiroshi Kunugi;Michiko Nakamura;Yoshimi Iijima;Yuji Okazaki;Teruhiko Higuchi
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2009 Volume 150B( Issue 8) pp:1110-1117
Publication Date(Web):
DOI:10.1002/ajmg.b.30941

Abstract

Recent progress in genotyping technology and the development of public databases has enabled large-scale genome-wide association tests with diseases. We performed a two-stage genome-wide association study (GWAS) of bipolar disorder (BD) in Japanese cohorts. First we used Affymetrix 100K GeneChip arrays in the analysis of 107 cases with bipolar I disorder and 107 controls, and selected markers that were nominally significant (P < 0.01) in at least one of the three models (1,577 markers in total). In the follow-up stage, we analyzed these markers using an Illumina platform (1,526 markers; 51 markers were not designable for the platform) and an independent sample set, which consisted of 395 cases (bipolar I + II) and 409 controls. We also assessed the population stratification of current samples using principal components analysis. After the two-stage analysis, 89 markers remained nominally significant (allelic P < 0.05) with the same allele being consistently over-represented in both the first and the follow-up stages. However, none of these were significant after correction for multiple-testing by false discovery rates. Sample stratification was virtually negligible. Collectively, this is the first GWAS of BD in the Japanese population. But given the small sample size and the limited genomic coverage, these results should be taken as preliminary. © 2009 Wiley-Liss, Inc.

Co-reporter:Kazuo Yamada;David J. Gerber;Yoshimi Iwayama;Tetsuo Ohnishi;Hisako Ohba;Tomoko Toyota;Jun Aruga;Yoshio Minabe;Susumu Tonegawa
PNAS 2007 Volume 104 (Issue 8 ) pp:2815-2820
Publication Date(Web):2007-02-20
DOI:10.1073/pnas.0610765104
The calcineurin cascade is central to neuronal signal transduction, and genes in this network are intriguing candidate schizophrenia susceptibility genes. To replicate and extend our previously reported association between the PPP3CC gene, encoding the calcineurin catalytic γ-subunit, and schizophrenia, we examined 84 SNPs from 14 calcineurin-related candidate genes for genetic association by using 124 Japanese schizophrenic pedigrees. Four of these genes (PPP3CC, EGR2, EGR3, and EGR4) showed nominally significant association with schizophrenia. In a postmortem brain study, EGR1, EGR2, and EGR3 transcripts were shown to be down-regulated in the prefrontal cortex of schizophrenic, but not bipolar, patients. These findings raise a potentially important role for EGR genes in schizophrenia pathogenesis. Because EGR3 is an attractive candidate gene based on its chromosomal location close to PPP3CC within 8p21.3 and its functional link to dopamine, glutamate, and neuregulin signaling, we extended our analysis by resequencing the entire EGR3 genomic interval and detected 15 SNPs. One of these, IVS1 + 607A→G SNP, displayed the strongest evidence for disease association, which was confirmed in 1,140 independent case-control samples. An in vitro promoter assay detected a possible expression-regulatory effect of this SNP. These findings support the previous genetic association of altered calcineurin signaling with schizophrenia pathogenesis and identify EGR3 as a compelling susceptibility gene.
Co-reporter:Mizuho Nakajima;Eiji Hattori;Kazuo Yamada;Yoshimi Iwayama
Journal of Human Genetics 2007 Volume 52( Issue 1) pp:86-91
Publication Date(Web):2007 January
DOI:10.1007/s10038-006-0084-3
Recent association studies suggest that polymorphisms in the promoter and exon 1 upstream region of the dopamine D4 receptor (DRD4) gene play a functional role in the development of common psychiatric illnesses, although there are also conflicting results. In this study, we re-sequenced this region to identify all genomic variants, and tested them for association with schizophrenia. A total of 570 Japanese schizophrenic cases with matched controls were studied by genotyping all identified/validated common polymorphisms (−1106T>C, −906T>C, −809G>A, −616G>C, −521T>C, −376C>T, −291C>T and 12-bp repeat) and a known microsatellite (120-bp tandem duplication) in the upstream region. A single nucleotide polymorphism (SNP) −809G>A in the promoter region was found to be significantly associated with disease (P=0.018 and 0.032 for allelic and genotypic comparisons, respectively), although not surviving after Bonferroni correction. Logistic regression analysis showed that a combination of the four polymorphisms, −809G>A, −616G>C, −291C>T and the 12-bp repeat, conferred a susceptibility to schizophrenia. These results suggest that the upstream variants have a primary functional effect in the etiology of schizophrenia in the Japanese population.
Co-reporter:Kazuo Yamada, Eiji Hattori, Yoshimi Iwayama, Tomoko Toyota, Yasuhide Iwata, Katsuaki Suzuki, Mitsuru Kikuchi, Tasuku Hashimoto, Nobuhisa Kanahara, Norio Mori, Takeo Yoshikawa
Schizophrenia Research (October 2015) Volume 168(Issues 1–2) pp:444-449
Publication Date(Web):1 October 2015
DOI:10.1016/j.schres.2015.08.018
There is consistent data from European cohorts suggesting a genetic contribution from the major histocompatibility complex (MHC) to the pathogenesis of schizophrenia. However, the genomic complexity and ethnicity-specific diversity found in the MHC cause difficulties in identifying causal variants or genes, and there is a need for studies encompassing the entire MHC region in multiple ethnic populations.Here, we report on association signals in the MHC region, with schizophrenia in the Japanese population. We genotyped and imputed a total of 10,131 single nucleotide polymorphisms (SNPs), spanning the entire MHC interval. The analysis included 3302 participants (1518 schizophrenics and 1784 healthy controls) from the Japanese population. In this study, we present evidence for association at rs494620, located in the SLC44A4 gene. The association survived after correction for multiple testing (unadjusted P = 7.78 × 10− 5, empirical P = 0.0357). The imputation results detected the highest association at rs707937 in the MSH5-SAPCD1 gene (imputed P = 8.40 × 10− 5). In expression analysis using postmortem brains from schizophrenia and control samples, MSH5-SAPCD1 showed marginally significant expression differences in Brodmann's area 46 (P = 0.044 by unpaired t test with Welch's correction, P = 0.099 by Mann–Whitney U test). Our study further strengthens evidence for the involvement of the MHC in schizophrenia across populations, and provides insight into population-specific mechanisms for the MHC region in schizophrenia susceptibility.
Co-reporter:Fabian N. Bangel, Kazuo Yamada, Makoto Arai, Yoshimi Iwayama, Shabeesh Balan, Tomoko Toyota, Yasuhide Iwata, Katsuaki Suzuki, Mitsuru Kikuchi, Tasuku Hashimoto, Nobuhisa Kanahara, Norio Mori, Masanari Itokawa, Oliver Stork, Takeo Yoshikawa
Progress in Neuro-Psychopharmacology and Biological Psychiatry (3 June 2015) Volume 59() pp:105-110
Publication Date(Web):3 June 2015
DOI:10.1016/j.pnpbp.2015.01.014
•Association analyses of SNPs in GLO1 and HAGH in Japanese samples were performed.•We genotyped 12 tag SNPs in 2012 schizophrenia patients and 2170 healthy controls.•HAGH SNPs were significantly associated with schizophrenia in males.•Expression levels of both genes in postmortem brain samples showed no changes.•The glyoxalase system alone cannot explain the elevated carbonyl stress in schizophrenia.Recent reports suggest that carbonyl stress might affect a subset of schizophrenia patients suffering from severe symptoms. Carbonyl stress protection is achieved by the glyoxalase system consisting of two enzymes, glyoxalase 1 and 2, which in humans are encoded by the genes GLO1 and HAGH, respectively. Glyoxalase 1 and 2 catalyze the detoxification of reactive alpha-oxoaldehydes such as glyoxal and methylglyoxal, which are particularly damaging components of carbonyl stress. Here, we investigated the role of the glyoxalase system in schizophrenia by performing association analyses of common genetic variants (n = 12) in GLO1 and HAGH in a Japanese sample consisting of 2012 schizophrenia patients and 2170 healthy controls. We detected a nominally significant association with schizophrenia (p = 0.020) of rs11859266, a SNP in the intronic region of HAGH. However, rs11859266 did not survive multiple testing (empirical p = 0.091). The variants in HAGH, rs11859266 and rs3743852, showed significant associations with schizophrenia in males at allelic and genotype levels, which remained persistent after multiple testing with the exception of rs3743852 for the genotype model. We further measured the mRNA expression of both genes in postmortem brain, but did not detect any changes in transcript expression levels between case and control samples or in sex-specific comparisons. Therefore, our findings suggest that an explanation of elevated carbonyl stress in a substantial part (reported as ~ 20%) of patients with schizophrenia will require the examination of a much larger cohort to detect risk alleles with weak effect size and/or other risk factors.
Co-reporter:Atsushi Takata, Yoshimi Iwayama, Yasuhisa Fukuo, Masashi Ikeda, Tomo Okochi, Motoko Maekawa, Tomoko Toyota, Kazuo Yamada, Eiji Hattori, Tetsuo Ohnishi, Manabu Toyoshima, Hiroshi Ujike, Toshiya Inada, Hiroshi Kunugi, Norio Ozaki, Shinichiro Nanko, Kazuhiko Nakamura, Norio Mori, Shigenobu Kanba, Nakao Iwata, Tadafumi Kato, et al.
Biological Psychiatry (15 March 2013) Volume 73(Issue 6) pp:532-539
Publication Date(Web):15 March 2013
DOI:10.1016/j.biopsych.2012.10.024
Co-reporter:Motoko Maekawa, Kazuo Yamada, Manabu Toyoshima, Tetsuo Ohnishi, Yoshimi Iwayama, Chie Shimamoto, Tomoko Toyota, Yayoi Nozaki, Shabeesh Balan, Hideo Matsuzaki, Yasuhide Iwata, Katsuaki Suzuki, Mitsuhiro Miyashita, Mitsuru Kikuchi, Motoichiro Kato, Yohei Okada, Wado Akamatsu, Norio Mori, Yuji Owada, Masanari Itokawa, Hideyuki Okano, et al.
Biological Psychiatry (15 July 2015) Volume 78(Issue 2) pp:116-125
Publication Date(Web):15 July 2015
DOI:10.1016/j.biopsych.2014.07.025
Somatostatin
GALACTOCEREBROSIDES
Docosapentaenoic acid
Complement factor B
4H-Imidazo[4,5-b]pyridine-4-hexanoicacid, a-amino-2-[[(4S)-4-amino-4-carboxybutyl]amino]-,(aS)-
trans-Vaccenic acid
9,12-Octadecadienoicacid
8,11,14-Eicosatrienoicacid, (8Z,11Z,14Z)-